Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

N/A

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06580418Recruiting

Evaluation of an Anti-TREM-1 Treatment on an ex Vivo Human Intestinal Model

Role: lead

NCT03463044Phase 1Completed

Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects

Role: lead

NCT03158948Phase 2Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock

Role: lead

NCT04429334Phase 2Completed

Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support

Role: lead

NCT04055909Phase 2Active Not Recruiting

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock

Role: lead

NCT04948840Not ApplicableUnknown

Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis

Role: collaborator

NCT04544891Completed

TREM-1 Pathway Activation in COVID-19

Role: collaborator

All 7 trials loaded